Gastroparesis is a medical disorder in which stomach lost their ability to empty itself of food. It usually happens due to damage to the vague nerve which regulate digestive system. A weakened vagus nerve prevents the muscles in the stomach and intestine from efficiently passing through the digestive system. The main causes for gastroparesis are uncontrolled diabetes, Parkinson’s disease, multiple sclerosis, amyloidosis, and other. They also have the ability to slow down stomach mobility which is the main factor prevent stomach from emptying. Some of the common symptoms of gastroparesis are vomiting undigested food, abdominal bloating, heartburn, poor appetite, and poor blood sugar level. These gastroparesis can cause some complication such as growth of bacteria if food stays in stomach for long and also people with both diabetes and gastroparesis face high blood sugar level when body leaves the stomach.
Access Full Report at https://www.databridgemarketresearch.com/de/reports/global-gastroparesis-market
Some of the factors responsible for the growth of Gastroparesis Marketare:
- Increasing cases of idiopathic gastroparesis: Idiopathic gastroparesis refers to unexplained cause gastroparesis, not prior gastric surgery, not diabetes, and not linked to other endocrine, rheumatologically or neurological causes of gastroparesis. The idiopathic gastroparesis and functional dyspepsia signs are similar. Some of the common symptoms of idiopathic gastroparesis are upper abdominal pain, vomiting, nausea, postprandial fullness, and other. Abdominal pain and discomfort may occur in patients with gastroparesis, but typically it is not the primary symptom, as it may occur in functional dyspepsia
- Rising surgeries can cause post-operative gastroparesis: After upper abdominal surgery, post-surgical gastroparesis (PSG) is known as a consequence of vagal nerve damage. After fundoplication and bariatric surgery, PSG is now being treated. PSG was also recorded after heart and lung transplantation, possibly due to opportunistic viral infection or immunosuppressive drug motor-inhibitory effects. The initial postoperative management of PSG should be conservative as many symptoms are resolved with time after abdominal surgery
The global gastroparesis market is segmented on the basis of type as idiopathic, diabetic, post- surgical, & others; drug class as prokinetic drugs, antiemetics, botulinum toxin injection, antidepressants, & others; treatment as jejunostomy, gastric electric stimulation, parenteral nutrition, diabetic gastroparesis, chronic gastroparesis, idiopathic gastroparesis, & post-operative gastroparesis and distribution channel as retail pharmacies, hospital pharmacies, and others.
Some of the launches and acquisition in the Gastroparesis Market are:
- In April 2017, Evoke Pharma announced that for its planned comparative exposure pharmacokinetic (PK) trial for its lead product candidate Gimoti, they are going to collaborate with Spaulding Clinical Research. Gimoti is a synthesized method of nasal delivery which can provide relief to the women from the symptoms of chronic and degenerative gastroparesis
- In March 2016, CAIRN DIAGNOSTICS announced the launch of their 13C-Spirulina Gastric Emptying Breath Test (GEBT). The GEBT is designed to assess the rate of solid-phase gastric emptying and to help diagnose delayed gastric emptying (gastroparesis) in adults with symptoms. This launch is very beneficial for rapid and accurate treatment of gastroparesis. There result can be presented in a comprehensive gastric emptying profile report
“According to Data Bridge Market Research, Global Gastroparesis Market is set to witness a substantial CAGR in the forecast period of 2019- 2026”
Few of the major competitors currently working in the global gastroparesis market are Medtronic, Neurogastrx, Inc., Endologic, Takeda Pharmaceutical Company Limited, ALLERGAN, Theravance Biopharma, Evoke Pharma, CAIRN DIAGNOSTICS, among others.
Increasing cases of diabetes and growing number of surgeries which is causing post-surgical gastroparesis are the factors which are expected to enhance the market growth. Availability of drugs which have the ability to control nausea and vomiting is also affecting the market positively. On the other, improvement in healthcare infrastructure and technological advancement and development in healthcare industry is also anticipated to drive the market.
Browse in Healthcare Related Reports@ https://www.databridgemarketresearch.com/de/report-category/healthcare/
